Coenzyme Q10 (ubiquinone, ubidecarenone) is one of the most widely taken supplements among older adults — the same population most likely to be on warfarin. Most people know that vitamin K interferes with warfarin (the vitamin K–warfarin story). Fewer know that CoQ10 is a close structural relative of vitamin K, and that it has been reported, in case series since 1994, to reduce warfarin’s anticoagulant effect. The evidence is genuinely mixed — a randomised trial found no effect — and that is exactly why the interaction deserves a careful, proportionate explanation rather than either alarm or dismissal.
The structural argument
Vitamin K (a naphthoquinone with a side chain) and coenzyme Q10 (a benzoquinone with a ten-unit isoprenoid side chain) share the quinone ring that does the chemical work in both molecules — accepting and donating electrons. Warfarin acts by blocking vitamin K epoxide reductase, the enzyme that recycles vitamin K so that clotting factors II, VII, IX and X can be carboxylated into their active forms. The hypothesis, first articulated when the clinical reports appeared, is that CoQ10 at supplemental doses may partially substitute for vitamin K in the carboxylation cycle, or may otherwise increase clotting-factor activity, thereby reducing warfarin’s effect and lowering the INR. The mechanism has never been fully confirmed, and an alternative explanation — that CoQ10 induces hepatic metabolism of warfarin via cytochrome P450 enzymes — has also been proposed on the basis of animal data. The pharmacology is plausible; it is not proven.
What the case reports showed
The first published report, in the Lancet in 1994, described three patients stabilised on warfarin whose INR fell after starting ubidecarenone and recovered after stopping it; in one case the sequence was repeated with the same result, which is the strongest kind of evidence a case report can offer (Spigset 1994). A Danish report in 1998 described a further case of reduced anticoagulant effect (Landbo & Almdal 1998). A longitudinal analysis of 171 warfarin patients over 16 weeks examined complementary-medicine use and outcomes; CoQ10 was among the supplements associated with an increased risk of bleeding events in that cohort, a finding in the opposite direction from the case reports and one the authors themselves flagged as requiring cautious interpretation given the small numbers (Shalansky et al. 2007). The systematic overview of warfarin interactions lists CoQ10 among agents with reported, lower-quality evidence of inhibiting warfarin’s effect (Holbrook et al. 2005).
What the trial showed
The only randomised, double-blind, placebo-controlled crossover trial enrolled 24 stable, long-term warfarin outpatients and gave them CoQ10 100 mg daily, Ginkgo biloba 100 mg daily or placebo, each for four weeks. Neither CoQ10 nor ginkgo produced any significant change in INR or in the warfarin dose required to maintain it (Engelsen et al. 2002). This is reassuring, and it is the reason most reference sources classify the interaction as “possible” or “minor” rather than established. It is also a small, short study at a single dose in patients who were already stable — which means it cannot exclude an effect in a subset of patients, at higher doses (200–300 mg is common in cardiology supplement use), in patients with unstable INR, or over longer periods. Absence of an effect in 24 people over four weeks is not absence of an effect.
How to weigh mixed evidence in practice
The clinical calculus is asymmetric. Warfarin has a narrow therapeutic window: an INR that drifts below range risks stroke or thrombosis; one that drifts above it risks haemorrhage. The consequence of an unrecognised interaction in either direction is serious, while the cost of the precaution is small — a few extra INR checks. The case reports are consistent in direction (INR falls), one includes a positive rechallenge, the structural rationale is coherent, and the trial that found nothing was small. On that basis the standard advice from anticoagulation services and pharmacology references is not “do not take CoQ10” but “do not start, stop or change the dose of CoQ10 without telling the clinician who manages your warfarin, and monitor INR more closely around any change.” The same logic applies to CoQ10 products combined with vitamin K2, fish oil or ginkgo, each of which carries its own interaction signal.
Who must ask a doctor first
Anyone taking warfarin (or the related coumarins acenocoumarol and phenprocoumon) should consult before starting CoQ10, and should plan an INR check within one to two weeks of starting and again after any dose change or discontinuation. Patients with labile INR or recent dose adjustments, those on high-dose CoQ10 (above 100 mg), those taking multiple supplements with anticoagulant or procoagulant signals, and those with mechanical heart valves — where sub-therapeutic INR is especially dangerous — deserve the most caution. The interaction does not appear to apply to the direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban), which do not act through vitamin K; the evidence on CoQ10 with these agents is limited, but there is no mechanistic reason to expect the same problem. And for patients taking CoQ10 alongside statins — its commonest use (CoQ10 and statins) — the warfarin question is simply one more item for the medication review.
The clinical bottom line
CoQ10 shares the quinone chemistry of vitamin K, and case reports since 1994 — including one with positive rechallenge — describe falling INR in warfarin patients; a small four-week randomised trial found no effect. Given warfarin’s narrow margin, the prudent path is not avoidance but disclosure and monitoring: tell the anticoagulation clinician before starting, stopping or changing CoQ10, and check the INR within two weeks of any change. The interaction is unproven; the cost of ignoring it is not.
Primary sources
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344(8933):1372–1373. doi:10.1016/S0140-6736(94)90736-6
- Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. Thromb Haemost. 2002;87(6):1075–1076. doi:10.1055/s-0037-1613135
- Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27(9):1237–1247. doi:10.1592/phco.27.9.1237
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106. doi:10.1001/archinte.165.10.1095
- Landbo C, Almdal TP. Interaction between warfarin and coenzyme Q10 [in Danish]. Ugeskr Laeger. 1998;160(22):3226–3227. PMID 9621804
Educational information on supplement quality and consumer protection, not medical advice.
Was this article helpful?
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
